PHG
Strong BuyFull HouseAI neutralKoninklijke Philips N.V. · Healthcare · Netherlands · $26.3B cap · $29.6M/day traded
$26.89 -0.1% · close 23 Oct · scored 24 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Report expected 3 Nov: the next-year EPS estimate has fallen 6.4% over the last 14 weeks.
As of 24 Oct 2026, MoatMap's StockRank for Koninklijke Philips N.V. (PHG) is 85/100, ranked against 24,000+ stocks in 35 markets (Quality 62, Value 69, Momentum 53, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Philips makes hospital imaging, patient monitoring and personal health products. It beat expectations in the second quarter but order intake disappointed, and forward estimates slipped 1.6% in four weeks. The company is still rebuilding trust and margins after the Respironics sleep-apnoea device recall and faces weaker demand in China, making this a recovery story rather than a proven compounder.
ABOUT KONINKLIJKE PHILIPS N.V.
Read
Koninklijke Philips N.V. is a global leader in health technology, specializing in diagnostic imaging, image-guided therapy, patient monitoring, and personal health products. The company has successfully transitioned from a diversified electronics conglomerate into a pure-play medical technology giant with a presence in over 100 countries. Its competitive moat is sustained by a massive patent portfolio, deep clinical partnerships, and integrated digital health platforms that connect hospital and home care.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.0B | 20.4B | 20.2B | 20.0B | 0.0% | 19.8B | 20.1B | 21.0B | 2.5% |
| EPS | -1.89 | -0.55 | -0.84 | 1.05 | — | 1.34 | 0.99 | 1.07 | 1.0% |
| Shares | 952.3M | 937.4M | 925.0M | 951.3M | -0.1% | 977.4M | — | — | — |
| Debt | 8.2B | 8.2B | 8.4B | 8.7B | 2.1% | 8.4B | — | — | — |
| Equity | 14.8B | 13.5B | 13.4B | 12.3B | -6.1% | — | — | — | — |
| Op CF | -193.8M | 2.4B | 1.8B | 1.3B | -25.9% | 2.6B | — | — | — |
| Inv CF | -1.7B | -712.4M | -641.9M | -825.6M | — | — | — | — | — |
| Fin CF | 560.1M | -949.9M | -555.6M | 119.9M | — | — | — | — | — |
No new 52-week low for 2 weeks, 14% above that low, but not back above a rising 50-day average.
The Momentum score still reads 53: it looks back six months, so it has not caught up with this fall.
Calmer than 76% of stocks we rank over the past year (28% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHG are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PHG | Koninklijke Philips N.V.(you) | $26.3B | 85 | Strong Buy |
| ARGX.BR | argenx SE | $55.1B | 84 | Strong Buy |
| QIA.DE | Qiagen N.V. | $10.4B | 91 | Strong Buy |
| RDC.DE | Redcare Pharmacy NV | $1.8B | 62 | Hold |
| PHARM.AS | Pharming Group N.V. | $803M | 37 | Hold |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.3B | 10 | Strong Sell |
| QURE | uniQure N.V. | $1.6B | 16 | Strong Sell |
| PRQR | ProQR Therapeutics N.V. | $182M | 17 | Strong Sell |
| ONWD.BR | Onward Medical N.V. | $161M | 11 | Strong Sell |
Peer medians: ROE 3.6% · P/E 30.9x · Gross margin 75.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.